Histogenics (HSGX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
August 10, 2017 6:30 AM EDTCompleted Enrollment in NeoCart® Phase 3 Clinical Trial Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency Market Research in U.S. and Japan Points to Potential Large Markets with Significant Unmet Need
WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended June 30, 2017.Â
We achieved a... More
